Alyeska Investment Group
YMAB

Alyeska Investment Group’s Y-mAbs Therapeutics YMAB Stock Holding History

Alyeska Investment Group’s Portfolio YMAB Stock Details YMAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-50,000
Closed -$1.33M – 475
2018
Q3 		$1.33M Buy
+50,000
New +$1.27M 0.01% 330

Other funds holding YMAB

SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
SCM
Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Alyeska Investment Group's YMAB Position: Q4 2018 in Review

Alyeska Investment Group sold out of Y-mAbs Therapeutics (YMAB) in Q4 2018, closing a stake of 50,000 shares — an estimated $1.33M sold.

Alyeska Investment Group first reported a position in YMAB in Q3 2018 and held it in 1 quarter. The position peaked at $1.33M in Q3 2018. 42 funds tracked by Wall St. Rank hold YMAB as of Q4 2018.

  • Alyeska Investment Group reported no remaining Y-mAbs Therapeutics position as of Q4 2018 after selling out during the quarter.
  • Alyeska Investment Group sold 50,000 Y-mAbs Therapeutics shares in Q4 2018, an estimated $1.33M.
  • Alyeska Investment Group first reported a position in Y-mAbs Therapeutics in Q3 2018 and held it in 1 quarter.
  • Alyeska Investment Group's Y-mAbs Therapeutics position peaked at $1.33M in Q3 2018.
  • 42 funds tracked by Wall St. Rank held Y-mAbs Therapeutics as of Q4 2018.

Based on Alyeska Investment Group's 13F filing for Q4 2018, filed 14 Feb 2019.